Screener
Quest Diagnostics DGX EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Quest Diagnostics’s reported figures.
Based on trailing twelve months.
The source filing: Quest Diagnostics’s 10-Q, filed July 23, 2026. Open the filing →
- Filed
- Jul 23, 2026, 4:16 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001022079-26-000070
FAQ
- What is Quest Diagnostics's EBITDA margin?
- Quest Diagnostics (DGX) reported EBITDA margin of 19.1% in Q2 2026.
- How has Quest Diagnostics's EBITDA margin changed year-over-year?
- Quest Diagnostics's EBITDA margin decreased by 0.3% year-over-year, from 19.2% to 19.1%.
- What is the long-term trend for Quest Diagnostics's EBITDA margin?
- Over 5 years (2020 to 2025), Quest Diagnostics's EBITDA margin has grown at a -4.9% compound annual growth rate (CAGR), from 24.7% to 19.3%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.
Ask your AI about Quest Diagnostics's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude